Outlook: Reassuringly positive operating performance
Skyepharma continues to maintain strong progress across the business. Revenue growth is driven by the products launched since 2012, with encouraging contributions from flutiform and Exparel. The improving operational leverage in the flutiform supply chain suggests continuing margin expansion though to 2018. We have reviewed our model, raising our forecasts for FY16 and beyond, and consequently our valuation increases by 11.5% from £354m or 338p a share to £395m or 377p a share.Skyland Petroleum is engaged in the licensing of copyright for feature films.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.